Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans

Journal of Pharmaceutical Sciences

Volumn 92, Issue 10, 2003, Pages 1990-2007

  Luttringer, Olivier ^a   Theil, Frank Peter ^a   Poulin, Patrick ^a   Schmitt Hoffmann, Anne H ^a,b   Guentert, Theodor Walter ^a   Lavé, Thierry ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b BASILEA PHARMACEUTICA INTERNATIONAL LTD   (Switzerland)

Author keywords

Allometric scaling; Biliary excretion; Clearance; Distribution; Hepatocyte; PBPK modeling

Indexed keywords

EPIROPRIM;

ADULT; ALLOMETRY; ANIMAL CELL; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG POTENTIATION; HUMAN; LIVER CELL; MALE; MATHEMATICAL ANALYSIS; MOUSE; NONHUMAN; NORMAL HUMAN; PARAMETER; PARTITION COEFFICIENT; PHYSICAL CHEMISTRY; PREDICTION; RAT; SCALE UP; STEADY STATE;

EID: 0141619296     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10461     Document Type: Article

References (32)

1. Prentis RA, Lis Y, Walker SR. 1988. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br J Clin Pharmacol 25:387-396.
2. Poulin P, Theil FP. 2002. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci 91:1358-1370.
3. Ritschel WA, Vachharajani NN, Johnson RD, Hussain AS. 1992. The allometric approach for interspecies scaling of pharmacokinetic parameters. Comp Biochem Physiol C 103:249-253.
4. Sanwald-Ducray P, Dow J. 1997. Prediction of the pharmacokinetic parameters of reduced-dolasetron in man using in vitro-in vivo and interspecies allometric scaling. Xenobiotica 27:189-201.
5. Leusch A, Troger W, Greischel A, Roth W. 2000. Pharmacokinetics of the M1-agonist talsaclidine in mouse, rat, rabbit and monkey, and extrapolation to man. Xenobiotica 30:797-813.
6. Mahmood I. 1998. Interspecies scaling of renally secreted drugs. Life Sci 63:2365-2371.
7. Lave T, Portmann R, Schenker G, Gianni A, Guenzi A, Girometta MA, Schmitt M. 1999. Interspecies pharmacokinetic comparisons and allometric scaling of napsagatran, a low molecular weight thrombin inhibitor. J Pharm Pharmacol 51:85-91.
8. Boxenbaum H, Ronfeld R. 1983. Interspecies pharmacokinetic scaling and the Dedrick plots. Am J Physiol 245:R768-R775.
9. Hutchaleelaha A, Chow HH, Mayersohn M. 1997. Comparative pharmacokinetics and interspecies scaling of amphotericin B in several mammalian species. J Pharm Pharmacol 49:178-183.
10. Mahmood I, Balian JD. 1996. Interspecies scaling: predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on CL. J Pharm Sci 85:411-414.
11. Boxenbaum H. 1984. Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab Rev 15:1071-1121.
12. Lave T, Schmitt-Hoffmann AH, Coassolo P, et al. 1995. A new extrapolation method from animals to man: Application to a metabolized compound, mofarotene. Life Sci 56:L473-L478.
13. Lave T, Coassolo P, Ubeaud G, et al. 1996. Interspecies scaling of bosentan, a new endothelin receptor antagonist and integration of in vitro data into allometric scaling. Pharm Res 13:97-101.
14. Lave T, Dupin S, Schmitt C, et al. 1997. Integration of in vitro data into allometric scaling to predict hepatic metabolic CL in man: Application to 10 extensively metabolized drugs. J Pharm Sci 86: 584-590.
15. Ward KW, Azzarano LM, Bondinell WE, et al. 1999. Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist. Drug Metab Dispos 27:1232-1241.
16. Mahmood I, Sahajwalla C. 2002. Interspecies scaling of biliary excreted drugs. J Pharm Sci 91: 1908-1914.
17. Arundel PA. 1997. A multi-compartmental model generally applicable to physiologically-based pharmacokinetics. (Astra-Zeneca, UK). Poster presentation during the third IFAC symposium. Modeling and control in biomathematical systems. University of Warwick, UK, 23-26 March.
18. Poulin P, Schoenlein K, Theil FP. 2001. Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs. J Pharm Sci 90:436-447.
19. Poulin P, Theil FP. 2002. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci 91:129-156.
20. Seglen PO. 1979. Hepatocyte suspensions and cultures as tools in experimental carcinogenesis. J Toxicol Environ Health 5:551-560.
21. Lave T, Dupin S, Schmitt C, et al. 1997. The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans. Pharm Res 14:152-155.
22. Nestorov IA, Aarons LJ, Arundel PA, Rowland M. 1998. Lumping of whole-body physiologically based pharmacokinetic models. J Pharmacokinet Biopharm 26:21-46.
23. Brown RP, Delp MD, Lindstedt SL, et al. 1997. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13:407-484.
24. Dedrick R, Bischoff KB, Zaharko DS. 1970. Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother Rep 54:95-101.
25. Mordenti J. 1985. Pharmacokinetic scale-up: Accurate prediction of human pharmacokinetic profiles from animal data. J Pharm Sci 74:1097-1099.
26. Pahlman I, Andersson S, Gunnarsson K, et al. 1999. Extensive biliary excretion of the sulfasalazine analogue, susalimod, but different concentrations in the bile duct in various animal species correlating to species-specific hepatobiliary toxicity. Pharmacol Toxicol 85:123-129.
27. Naritomi Y, Terashita S, Kimura S, et al. 2001. Prediction of human hepatic CL from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 29:1316-1324.
28. Dresser MJ, Gray AT, Giacomini KM. 2000. Kinetic and selectivity differences between rodent, rabbit, and human organic cation transporters (OCT1). J Pharmacol Exp Ther 292:1146-1152.
29. Niinuma K, Kato Y, Suzuki H, et al. 1999. Primary active transport of organic anions on bile canalicular membrane in humans. Am J Physiol 276: G1153-G1164.
30. Ishizuka H, Konno K, Shiina T, et al. 1999. Species differences in the transport activity for organic anions across the bile canalicular membrane. J Pharmacol Exp Ther 290:1324-1330.
31. Moghe PV, Berthiaume F, Ezzell RM, et al. 1996. Culture matrix configuration and composition in the maintenance of hepatocyte polarity and function. Biomaterials 17:373-385.
32. Liu X, Chism JP, LeCluyse EL, et al. 1999. Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. Drug Metab Dispos 27:637-644.